Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Its pipeline consists of five product candidates, including potential novel therapeutics for hyperhidrosis, atopic dermatitis, allergic contact dermatitis, acne and psoriasis. Brickell's management team and board of directors have extensive experience in product development, having served in leadership roles at several pharmaceutical and successful start-up companies. Its strategy is to leverage this experience to in-license, acquire, develop and commercialize products that Brickell believes can be successful in the dermatology marketplace.
Location: United States, Colorado, Boulder
Total raised: $17M
Investors 3
| Date | Name | Website |
| 06.11.2022 | Hercules C... | htgc.com |
| - | VisionTech... | visiontech... |
| - | Technology... | pivotcente... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.02.2015 | Series C | $10M | - |
| 26.02.2013 | Series B | $7M | - |
Mentions in press and media 18
| Date | Title | Description |
| 02.02.2022 | 4SC pulls plug on domatinostat; Pharming says leniolisib meets both endpoints | The management board of 4SC has discontinued its domatinostat program after the most recent clinical data has been released, the company announced Tuesday. The orally administered small molecule class I selective inhibitor was being develop... |
| 10.11.2021 | Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Form 8-K | Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update Announced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patie... |
| 10.11.2021 | Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update | Announced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients; plan to submit a New Drug Application (NDA) to the FDA in mid-2022 Development of DYRK1... |
| 07.10.2021 | Brickell Biotech : Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide... | Sofpironium bromide gel, 15% was generally well-tolerated Plan to submit a New Drug Application (NDA) to the FDA in mid-2022 Management to host webcast and conference call today at 8:30 a.m. ET to present the topline results BOULDER, Colo.,... |
| 01.09.2021 | Brickell Biotech : Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer | BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated p... |
| 16.08.2021 | Brickell Biotech : Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis | Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 NDA submission for sofpironium bromide gel, 15% anticipated in mid-2022 pending Phase 3 outcome BOULDER, Colo., Aug. 16, 2021 (GLOBE N... |
| 12.08.2021 | Brickell Biotech : Reports Second Quarter 2021 Financial Results and Provides Corporate Update | Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study - - - Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 - - ... |
| 12.08.2021 | Brickell Biotech : Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study (Form 8-K) | Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study - - - Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 - - ... |
| 23.07.2021 | Brickell Biotech closes on $8M fundraising round | Brickell Biotech Inc. (Nasdaq: BBI), a developer of skin disease therapies, closed on $8.05 million in new funding Wednesday, more than the company anticipated. Earlier this week, Brickell said it expected to raise $7 million. “The company ... |
| 22.07.2021 | Brickell Biotech : Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter's Option to Purchase Additional Shares | BOULDER, Colo., July 22, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for ... |
Show more